Navigation Links
Toll-like receptor 4-mediated apoptosis of hippocampal neurons
Date:12/4/2013

Toll-like receptor 4 (TLR4) antibody, protein kinase B (AKT) inhibitor, LY 294002, and glycogen synthase kinase 3β (GSK-3β) inhibitor, LiCl, were used by Yu He and colleagues from Nantong University, China to attenuate or augment the effects of the TLR4-phosphatidylinositol 3 kinase (PI3K)/AKT-GSK-3β signaling pathway so as to identify the participation of this signaling system in the apoptosis of hippocampal neurons. Their findings showed that the apoptotic ratio of hippocampal neurons stimulated by lipopolysaccharide was significantly higher compared with the control group. Both the expression of P-AKTSer473 and P-GSK-3βSer9 in hippocampal neurons stimulated by lipopolysaccharide decreased compared with the control, while the level of active Caspase-3 and the ratio of Bax/Bcl-2 were significantly increased. The level of active Caspase-3 and the ratio of Bax/Bcl-2 in hippocampal neurons treated with TLR4 antibody or the GSK-3β inhibitor, LiCl, decreased before intervention with lipopolysaccharide, but increased after treatment with the AKT inhibitor, LY294002. These findings, published in the Neural Regeneration Research (Vol. 8, No. 29, 2013), suggest that the TLR4-PI3K/AKT-GSK3β signaling pathway may be involved in lipopolysaccharide-induced apoptosis of hippocampal neurons. Thus, a new target for treatment of neurodegenerative diseases would be to block apoptosis signaling pathways in vulnerable neurons.


'/>"/>

Contact: Meng Zhao
eic@nrren.org
86-138-049-98773
Neural Regeneration Research
Source:Eurekalert  

Page: 1

Related medicine news :

1. Eliminating the good cholesterol receptor may fight breast cancer
2. Breast stem-cell research: Receptor teamwork is required and a new pathway may be involved
3. Opioid receptors as a drug target for stopping obesity
4. Cloned receptor paves way for new breast and prostate cancer treatment
5. Caffeines effect on the brains adenosine receptors visualized for the first time
6. ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours
7. Group Therapy: New approach to psychosis treatment could target multiple nervous system receptors
8. Rewriting a receptors role
9. Brain-imaging study links cannabinoid receptors to post-traumatic stress disorder
10. Researchers target HER1 receptor for peptide cancer vaccine, therapeutic agents
11. $5.9 million grant adds androgen receptor as a new driver and target in breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Toll-like receptor 4-mediated apoptosis of hippocampal neurons
(Date:4/26/2017)... Hackensack, N.J. (PRWEB) , ... April 26, 2017 ... ... fluency, Inc. in Hackensack, N.J. has been honored by Enterprising Women magazine ... program that recognizes the world’s top women business owners. Winners have demonstrated that ...
(Date:4/26/2017)... ... 2017 , ... RawTrition now brings you BioEnergy which is a powder capsule ... , RawTrition is taking nutrients to the next level! The superfoods in ... raw form (unlike the synthetically made options that are on the market). , Founder ...
(Date:4/26/2017)... FL (PRWEB) , ... April 26, 2017 , ... ... and human performance, is proud to announce that it has received 510(k) clearance ... technologies, the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and ... its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne ...
(Date:4/25/2017)... ... 2017 , ... The doctors at Wall Centre Dental are now expanding their ... require sedation to receive dental care. The doctors offer three treatment options to put ... to oral surgery, at their dental office in Vancouver. Wall Centre Dental is currently ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology: